Ask AI
ProCE Banner Activity

DESTINY-Breast11: Phase III Study of Neoadjuvant T-DXd With or Without THP vs ddAC-THP in Patients With High-Risk HER2+ EBC

Conference Coverage
Slideset

In the global, multicenter, phase III DESTINY-Breast11 trial, neoadjuvant T-DXd followed by trastuzumab plus pertuzumab and paclitaxel (THP) was associated with higher rates of pathologic complete responses and an improved safety profile when compared with standard of care ddAC-THP in patients with high-risk HER2-positive early breast cancer. 

Released: October 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly